Proactive fecal calprotectin (FC) home monitoring every 2 months did not reduce risk or delay time to symptomatic ulcerative colitis (UC) flare compared to standard care.
No differences were seen in secondary outcomes including healthcare utilization, medication use, or quality of life.
Among patients who escalated therapy after confirmed high FC, flare frequency was numerically lower but without statistically significant risk reduction.
The study suggests that home FC monitoring alone, without a strict escalation protocol, may not prevent UC flares, indicating a need for further research on optimal use and intervention strategies.
